
Antonio Calles/ruberinternacional.es
Sep 9, 2025, 05:48
Antonio Calles on Conflicts Between NeoADAURA and FLAURA-2 Results in EGFR-Mutant Lung Cancer
Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared a post on X:
“Neoadjuvant chemotherapy adds nothing to osimertinib in terms of ctDNA clearance or pathological responses in resectable EGFR mutant lung cancer (neoADAURA trial).
In my mind, this somehow conflicts with the results from FLAURA -2 in the metastatic setting, where the addition of chemo to osimertinib improves clinical outcomes. Is because different biology (eg., less clonality in smaller tumors?).”
More posts featuring Lung cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 05:35
Sep 9, 2025, 02:16
Sep 9, 2025, 02:03
Sep 9, 2025, 01:48
Sep 9, 2025, 01:43
Sep 9, 2025, 00:59
Sep 9, 2025, 00:46
Sep 8, 2025, 17:37